A phase I, randomized, placebo controlled, parallel group, single dose study to evaluate the effects of PF-00572778 [PF-572778] and alprazolam on a naloxone challenge in healthy adult subjects

Trial Profile

A phase I, randomized, placebo controlled, parallel group, single dose study to evaluate the effects of PF-00572778 [PF-572778] and alprazolam on a naloxone challenge in healthy adult subjects

Discontinued
Phase of Trial: Phase I

Latest Information Update: 16 Sep 2009

At a glance

  • Drugs Alprazolam; PF 572778
  • Indications Generalised anxiety disorder
  • Focus Pharmacodynamics
  • Sponsors Pfizer
  • Most Recent Events

    • 16 Sep 2009 Actual end date (Feb 2008) and actual number of patients (47) added as reported by ClinicalTrials.gov.
    • 16 Sep 2009 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
    • 15 Jan 2008 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top